



Cancer Immunotherapy Using Checkpoint Inhibitors: Future Directions 3.0

Guest Editor:

Prof. Dr. Donald J. Buchsbaum

Department of Radiation
Oncology, University of Alabama
at Birmingham, Birmingham, AL
35294, USA

Deadline for manuscript
submissions:

closed (30 August 2023)

Message from the Guest Editor

Immune checkpoints are regulators of the immune system. Checkpoint inhibitor monoclonal antibodies that block CTLA-4 or PD1/PD-L1 have been approved for the treatment of several cancers including melanoma, bladder, and lung cancer. Despite increases in overall survival, not all patients respond to treatment. Approaches to increase survival include the use of new checkpoint inhibitors to regulate T cell responses and other immune effectors, identification of predictive biomarkers, modulators of the immune response, and the use of combination immunotherapies and therapies. This Special Issue will incorporate, but is not limited to, the following sub-topics:

Novel checkpoints and inhibitors; Immune checkpoint activators; Immune regulation; Biomarkers predictive of response; Immunomodulatory agents including cytokines; Targeting of innate immunity; Adaptive immunity; Neoantigen targeted therapies; T cell exhaustion; Targeting of immunosuppressive cells; Mechanisms of tumor immune cell evasion; Modulation of the immunosuppressive tumor microenvironment; Targeting Wnt ligand signaling





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Maurizio Battino

Department of
Odontostomatologic and
Specialized Clinical Sciences,
Sez-Biochimica, Faculty of
Medicine, Università Politecnica
delle Marche, Via Ranieri 65,
60100 Ancona, Italy

Message from the Editor-in-Chief

The International Journal of Molecular Sciences (*IJMS*, ISSN 1422-0067) is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, molecular biophysics, molecular medicine, and all aspects of molecular research in chemistry. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Biochemistry & Molecular Biology*) / CiteScore - Q1 (*Inorganic Chemistry*)

Contact Us

*International Journal of Molecular
Sciences* Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/ijms
ijms@mdpi.com
X@IJMS_MDPI